Fewer than one in 10 people that would benefit from obesity jabs like Wegovy can access them, states the WHO as it releases its first advice on the therapies.
With in excess of 1,000,000,000 people worldwide currently living with obesity, it is urging increased and just access to these injectable treatments.
According to forecasts, over two billion will be obese by 2030 unless action is taken.
"The latest guidance recognises that excess weight is a lifelong illness that can be managed with thorough and continuous support," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are major hurdles to widespread availability to the treatments that can assist patients in reducing substantial weight, says the organization.
GLP-1 Therapy Supply Crisis
Even in the present most favorable case, the production of these medications could only cover about 100 million people – under 10% of the global need, as stated by the WHO.
The advice urges nations and manufacturers to widen access, through measures like patent sharing.
The intellectual property rights on the active ingredient – the primary ingredient of the drug Wegovy – is scheduled to end in a number of nations in 2026.
How Obesity Injections Function
The injections mimick a body's own hormone to delay gastric emptying, curb appetite and enhance satiety so users eat less.
Patients commonly begin shedding pounds after several weeks of commencing the once-weekly jabs.
Studies points to patients may put most of the weight back on within a year of halting the treatment, when their usual appetite return.
To be above a healthy weight increases your chance for experiencing medical conditions, like diabetes, heart disease, brain attack, and specific malignancies.
Obesity impacts individuals in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, per the WHO.
